News

SPI-026 was discovered by Dr Edda Speikerkoetter and is being developed with the help of Dr Roham Zamanian at Stanford University. The company said that SPI-026 prevented the

The Phase III program included two pivotal 24-week trials PINNACLE 1 and PINNACLE 2, which evaluated the potential of this fixed-dose combination. Glycopyrronium is a long-acting muscarinic antagonist

Initiated by the UK Government, the $100m Dementia Discovery Fund will get investment from Alzheimer’s Research UK, together with pharmaceutical companies including GSK, JNJ, Biogen Idec and Eli

Filed in the US District Court for the Southern District of New York, the plaintiffs in the lawsuit are Elyse Dickerson and Susan Orr. They claim that the

Under the deal, the two parties will share intellectual property and jointly fund ten research projects, resulting in the design of multiple new inhibitors of the MTH1 protein,

As part of the deal, Roche will provide study drug and Celldex will be responsible for conducting and funding the trial, which is scheduled to be initiated later

In 2008, Lupin acquired 60% equity stake in PD, which is involved in distribution of a range of branded, generic prescription medicines and over-the-counter (OTC) products in South

The combined company will be responsible for developing new medicines that address unmet medical needs in critical therapeutic areas and is expected to have combined annual pro forma

Jakavi is the first targeted treatment approved by the EC for these patients in the European Union (EU) who are resistant to or intolerant of hydroxyurea. The European